Gubra registers first-in-human trial for obesity peptide GUB-UCN2
The three-part Phase 1/2 study will test safety and pharmacokinetics of the urocortin-2 analog in lean, obese and type 2 diabetes cohorts ahead of a December 2028 completion.
Executive Summary
- Gubra has registered a first-in-human trial for a new obesity and metabolic-disease candidate, structured to test safety and drug behavior across healthy, obese, and diabetic participants before any efficacy question is asked.
- The three-part structure signals a methodical approach to de-risking the compound across the metabolic spectrum in a single protocol, rather than running separate early studies in each population.
- The trial enters a large and mechanism-diverse obesity field where the candidate's own target has not been placed, leaving it without a direct comparator among the incumbent GLP-1, GIP, and amylin-pathway programs.
- The readout that matters is years away, and the substance of the setup is how cleanly the tolerability and pharmacokinetic data land across all three participant groups when the study eventually reports.
The trial
The study, listed under NCT07702890, is not yet recruiting and targets enrollment of 188 participants, with a primary completion date of December 1, 2028. It is structured in three parts: Part 1 enrolls healthy participants with a body mass index of 20 to 29.9 kg/m2, Part 2 enrolls male participants with obesity (BMI 30 to 35 kg/m2), and Part 3 enrolls participants with obesity (BMI 30 to 45 kg/m2) or with type 2 diabetes and stable antidiabetic therapy (BMI 27 to 35 kg/m2, HbA1c at or below 8.5%). The trial's primary outcome measure is the number of treatment-emergent adverse events tracked from baseline through week 22, with a battery of secondary pharmacokinetic measures, including area-under-the-curve and maximum concentration values, tracked over the same window. NCT07702890A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2DNCT07702890
What the design tests
A safety and pharmacokinetics-first design, with adverse-event incidence as the primary endpoint, is built to establish whether GUB-UCN2 is tolerable and how it behaves pharmacokinetically across a widening range of body weight and metabolic status, from lean and healthy through obese and diabetic. That progression, run inside one first-in-human protocol rather than as sequential separate studies, indicates the sponsor is trying to characterize the compound across its eventual target population in a single dataset before deciding whether the profile supports later-stage development. The study is not registered as registrational. NCT07702890A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2DNCT07702890
The competitive field
The obesity trial landscape is large and mechanistically concentrated around GLP-1 receptor agonism, with Eli Lilly and Novo Nordisk each running dozens of active trials and tens of thousands of enrolled patients behind drugs such as tirzepatide, semaglutide, and retatrutide. None of the named comparators identified in the indication, including semaglutide, tirzepatide, and setmelanotide, share GUB-UCN2's mechanism, and no competitor trial in the sourced obesity or type 2 diabetes landscape was flagged as a direct comparator. That leaves GUB-UCN2 without an established mechanistic precedent inside a field otherwise dominated by incretin-pathway drugs, a structural position distinct from, rather than crowded by, the GLP-1 class.
Sponsor context
This is the only trial currently listed for GUB-UCN2 and the only active study in Gubra's registered pipeline. The registry record has generated a single change event since being added, and the protocol carries a stability label of Stable with no amendments logged beyond the initial filing.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.